ClinicalTrials.gg
CompletedNCT03882892Updated May 10, 2024

Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)

A Phase 3 interventional study of Ezetimibe and Atovastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 86 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2002, 24 years 3 months ago, and no results have been posted to the registry.
  • Registered 18 years 1 month after the study started (first participant enrolled Feb 2001, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 86 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Planned enrollment
20th of 97
400 · median 148
Started
2001
with 1 other
Phase 3
50 of 98
1 open now
Registered
85th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 20th largest by planned enrollment of the 97 interventional ones that give a count, is one of 2 that started in 2001, is one of 50 in phase 3, and was the 85th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 86 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to examine the long-term safety and tolerability of ezetimibe (SCH 58235) 10 mg once daily or placebo in combination with atorvastatin (10 to 80 mg/day) for up to 12 consecutive months in participants with primary hypercholesterolemia.

Read the detailed description

This study is a long-term extension study of the protocol P00692 parent study.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 86 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has successfully completed the 12-week double-blind, efficacy and safety parent study (P00692).
  • If female, has a negative pregnancy test prior to study entry and, if of , agrees to practice an effective barrier method of for the duration of the study and for 30 days after the last statin dose.
  • If female receiving hormone therapy, a stable estrogen (ERT), estrogen/progestin (HRT) or raloxifene regimen must be maintained during the study period.
  • Is willing to continue to follow their prescribed National Cholesterol Education Program (NCEP) Step 1 diet for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Has discontinued from the parent study (P00692) prior to study completion.
  • Is in a situation, or has any condition which, in the opinion of the investigator may interfere with optimal participation.
  • Is a pregnant or lactating female.
  • Is (HIV) positive.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
400 participants (estimated)

Study arms

  • Placebo comparator
    Placebo + Atorvastatin

    Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.

    Drug: Atovastatin · Drug: Placebo

  • Experimental
    Ezetimibe + Atorvastatin

    Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.

    Drug: Ezetimibe · Drug: Atovastatin

Interventions

  • Ezetimibe 10 mg tablets

    Also known as: SCH 58235

  • DrugAtovastatin

    Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg

  • DrugPlacebo

    Placebo tablets matched to ezetimibe

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing ≥1 Adverse Event (AE)

    Time frame: Up to 12 months

  2. Percentage of Participants Discontinuing from Study Treatment due to an Adverse Event (AE)

    Time frame: Up to 12 months

Secondary outcomes

  1. Mean Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline and 1.5, 3, 6, 9, and 12 months

  2. Mean Percent Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C)

    Time frame: Baseline and 1.5, 3, 6, 9, and 12 months

  3. Mean Percent Change from Baseline in Triglyceride Levels

    Time frame: Baseline and 1.5, 3, 6, 9, and 12 months

  4. Mean Percent Change from Baseline in Total Cholesterol (TC)

    Time frame: Baseline and 1.5, 3, 6, 9, and 12 months

  5. Mean Percent Change from Baseline in Calculated Low-Density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline and 1.5, 3, 6, 9, and 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, Veltri EP. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004 Jul;58(7):653-8. doi: 10.1111/j.1368-5031.2004.00278.x. PubMed 15311720 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2001 to primary completion in Aug 2002, 18 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Mar 20, 2019
StartActual
Feb 2, 2001
Primary completionActual
Aug 8, 2002
CompletionActual
Aug 8, 2002
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03882892
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Mar 20, 2019
Start date
Feb 2, 2001
Primary completion
Aug 8, 2002
Completion
Aug 8, 2002
Last update
May 10, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion